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Abstract  
Objective: Non-response to antidepressant treatment is a substantial problem in Primary Care, and 
many patients with depression require additional second-line treatments. This study aimed to 
examine the prevalence and patterns of antidepressant switching in the UK, and identify associated 
demographic and clinical factors. 
 
Method: Cohort analysis of antidepressant prescribing data from the Clinical Practice Research 
Datalink; a large, anonymised, UK primary care database. The sample included 262,844 patients who 
initiated antidepressant therapy between 1st January 2005 and 31st June 2011.  
 
Results: 9.3% of patients switched to a different antidepressant product, with most switches (60%) 
occurring within eight weeks of the index date. The proportion switching was similar for SSRIs, TCAs 
and other antidepressants (9.3%, 9.8% and 9.2% respectively). Most switches were to an SSRI 
(64.5%), and this was the preferred option regardless of initial antidepressant class. Factors 
predictive of switching included male gender, younger (<18 years) and older age (>60 years), and 
history of self-harm and psychiatric illness.  
 
Conclusion:  
Over one in every eleven patients who initiates antidepressant therapy will switch medication, 
suggesting that initial antidepressant treatment has been unsatisfactory. Evidence to guide choice of 
second-line treatment for individual patients is currently limited. Additional research comparing 
different pharmacological and psychological second-line treatment strategies is required In order to 
inform guidelines, and improve patient outcomes.  
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Introduction  
Major Depressive Disorder is a common psychiatric disorder, and is among the leading 
causes of disability worldwide (Ferrari et al., 2013). Guidelines from the National Institute for Health 
and Clinical Excellence, (NICE) in the UK (National Institute for Health and Clinical Excellence, 2009) 
highlight the importance of adequate treatment duration, and recommend that antidepressants 
(ADs) should be continued for at least six months following remission to reduce risk of relapse. 
Guidelines in America suggest a similar period of 4-9 months (American Psychiatric Association, 
2010). However, a substantial proportion of patients discontinue AD treatment before this. Common 
reasons for early discontinuation include lack of efficacy and intolerance (Mitchell and Selmes, 2007, 
Thomas et al., 2013c, Fava, 2000, Linden et al., 2000).  
Non-response to AD treatment is common in UK Primary Care, with 55% of patients not 
responding to medication despite adequate dose and duration of treatment (Thomas et al., 2013c). 
Findings from clinical trials suggest that for many patients, remission is not achieved with 
monotherapy alone, and additional second-step treatments are often required (Rush et al., 2006, 
Huynh and McIntyre, 2008). Switching to another AD can improve remission rates, for example in 
the STAR*D trial, approximately 1 in 4 patients who did not respond/were intolerant to an initial 
SSRI treatment achieved remission after switching ADs (Rush et al., 2006, Huynh and McIntyre, 
2008).  
Reported switching rates from existing studies range from 8% to 40% (Milea et al., 2010, Wu 
et al., 2013, Saragoussi et al., 2012, Andersson Sundell et al., 2013, Marcus et al., 2009, Ball et al., 
2014, Schultz and Joish, 2009), and there is some evidence to suggest that the likelihood of switching 
may be influenced by demographic and clinical factors such as age, gender, history of /current 
psychiatric disorder, and severity of depression (Milea et al., 2010, Saragoussi et al., 2012, Marcus et 
al., 2009). However, the level and pattern of AD switching amongst Primary Care patients in the UK 
remains poorly understood. A better understanding of the products that demonstrate high levels of 
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switching would be of benefit, as this may be indicative of poor response or tolerability, and could 
inform guidance on initial AD choice.    
This paper examines switching patterns of ADs amongst patients who initiated treatment 
between 1995 and 2011, using data extracted from the Clinical Practice Research Datalink (CPRD); a 
large, anonymised, Primary Care database in the UK. Our objectives were to: 
1. Describe patterns of AD switching according to product type and drug class 
2. Examine demographic characteristics and clinical factors associated with AD switching, 
including age, gender and psychiatric illness.  
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Methods 
Data source 
The Clinical Practice Research Datalink (CPRD) (www.cprd.com) is one of the largest primary 
care databases in the world and contains anonymised electronic records from over 4 million active 
patients, representing about 6.9% of the UK population (Herrett et al., 2015). The database contains 
information on diagnosis, symptoms, prescriptions, referrals and test results, as well as demographic 
and administrative information. This information is routinely entered by GPs and their staff onto 
their computer systems, and then is extracted, anonymised and quality checked. The patient 
population captured in the database is representative of the overall UK population in terms of age, 
sex and ethnicity (Herrett et al., 2015). The MHRA Independent Scientific Advisory Committee (ISAC) 
reviewed the study protocol for scientific quality (protocol #: 15_100). The CPRD group has obtained 
ethics approval from a multicentre research ethics committee for all purely observational research 
using CPRD data- that is, studies that do not include patient involvement and are anonymised.  
 
Study population  
All patients who initiated AD treatment between 1st January 2005 and 31st June 2011 were 
identified. The date of their first antidepressant prescription during this time period was defined as 
the index date. Analyses were restricted to ‘acceptable’ patient records from practices that met the 
CPRD quality criteria and contributed data for the entire study period (Herrett et al., 2015). To 
ensure patients were newly started on AD treatment, they were required to be registered with a 
CPRD contributing practice for at least 3 years before the index date, without an AD prescription 
during this time. Continuous registration for at least 6 months following the index date was also 
required, to ensure there was sufficient time for a treatment switch.  Patients were excluded if they 
were <14 years of age or if they initiated treatment with more than one AD. 
 
7 
 
   Treatment change  
Only the first AD treatment episode was considered. The intended duration of treatment 
was estimated from the dosing instructions and the quantity prescribed. Where no dosage 
instructions were provided, the median for the product type was used. Consecutive prescriptions 
were considered to be part of the same treatment episode if the gap between the expected end of 
one prescription and the start of another was 30 days or less.  
A switch in AD medication was defined as a discontinuation of the index (or first-line) AD, 
and prescription of a new (second-line) AD within 30 days of the presumed end date of the first line 
treatment, and, no overlap of the two drugs for more than 30 days. Patients who had a change in AD 
treatment together with a consecutive repeat prescription of the index AD were categorised as 
augmentation rather than a treatment switch. Patients were also categorised as augmentation if 
there was an overlap of the two AD drugs for >30 days. Where more than one switch occurred 
during the same treatment episode, we focused on the first switch only.  
 
Analysis strategy 
AD medications were identified using section 4.3. of the British National Formulary, and 
classified into three categories based on their proposed method of action (Appendix 1): Selective 
Serotonin Reuptake Inhibitors (SSRIs), Tricyclic antidepressants (TCAs), and ‘other’ antidepressants, 
largely consisting of Mirtazapine and Venlafaxine. Prescriptions of Amitriptyline (<75mg) and 
Nortriptyline were excluded, as has been done previously (Marcus et al., 2009), as they are 
commonly prescribed for indications other than depression, particularly pain (Ilyas and Moncrieff, 
2012, Noordam et al., 2015). However sensitivity analysis including these medications was also 
conducted.  
The proportion of patients who switched AD and the proportion augmenting first-line treatment 
with a second AD product were calculated. As the focus of this paper is on AD switching AD 
augmentation was not investigated further. The pattern of AD switching was examined according to 
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both individual product type and AD class. Descriptive analysis of first and second line AD were 
performed using summary statistics (percentages for categorical variables and median for 
continuous variables). Primary analysis used univariable logistic regression models to investigate the 
association between switching and a number of patient demographic and clinical characteristics, 
including age and sex, and lifetime history of self-harm, any psychiatric illness, and depression and 
anxiety specifically. As decisions regarding AD choice may be particularly influenced by recent self-
harm history, we also examined associations with past year self-harm. Secondary analysis was also 
conducted i) adjusting for age and gender, and ii) additionally adjusting for psychiatric problems, in 
order to explore whether associations were independent of these factors. Psychiatric illness and self-
harm were identified in CPRD using Read Codes (Thomas et al., 2013a, Davies et al., 2013, Thomas et 
al., 2013b) which are available on request from the authors.  Read codes are a coded thesaurus of 
clinical terms used in General Practice in the United Kingdom. They provide the standard vocabulary 
by which clinicians can record patient findings and procedures in IT systems across primary and 
secondary care (Health & Social Care Information Centre). 
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Results 
The final sample eligible for analysis included 262,844 patients (94,280 males, 168,564 
females, mean age at index date 47.8 years) from 419 GP practices. Table 1 shows the pattern of AD 
prescribing according to AD product and drug class. The majority (86.9%) were prescribed an SSRI as 
the index AD, 6.3% were prescribed a TCA, and 6.8% another AD. The most common ADs prescribed 
as a first-line treatment were Citalopram (48.5%) and Fluoxetine (26.0%), which together accounted 
for 74.5% of all index ADs.  In total, 24,471 (9.3%) of patients who initiated AD treatment switched to 
another AD. The number of patients who augmented AD treatment with a second AD was 4,630 
(1.8%).   
 The total proportion of patients who switched AD was similar for each of the three classes 
investigated; 9.8% of those prescribed a TCA, 9.3% of those prescribed an SSRI and 9.2% of those 
prescribed another AD. The median time to treatment change was 44 days (interquartile range 22 
days, 98 days). The time to switch was slightly longer amongst those prescribed an SSRI than a TCA 
or other AD (45, 38, and 35 days respectively). Around a quarter of the sample (24.4%) switched AD 
within the time frame recommended by the NICE guidelines (4-8 weeks); 35.5% switched AD before 
4 weeks and 40.1% after 8 weeks.  
Nearly two thirds of AD switches were to an SSRI (64.5%), 24.8% switched to the “other AD” 
class and 10.7% to a TCA. A switch to an SSRI was the most frequent pattern, regardless of the index 
drug (Table 2), however this was proportionately more common amongst those prescribed another 
AD (80.2% of switches from this drug class) or a TCA (75.4%), than from those prescribed an SSRI 
(62.4%) (Figure 1). The most common ADs prescribed as a second-line treatment were Citalopram 
(25.8% of those who switched AD), Fluoxetine (17.5%), Mirtazapine (16.2%) and Sertraline (13.0%). 
The ten most common switching patterns, accounting for almost two-thirds of all AD switches, are 
shown in supplementary Table 1.  
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Characteristics associated with switching 
The demographic and clinical factors associated with AD switching are shown in Table 3. 
1) Gender: The odds of switching AD were 21% higher amongst males than females (OR 1.21, 95% CI 
1.18, 1.24; 8.7% of females switched AD compared with 10.4% of males). Effect estimates were 
similar when adjusting for age and history of psychiatric illness (Supplementary Table 2). Females 
were somewhat more likely to be prescribed a TCA as the index AD than males (8.1% vs. 2.9%), 
however the overall pattern of switching between ADs was similar across genders (results available 
on request). 
 
2) Age: The proportion of patients switching ADs was similar for those aged 18-30, 31-35 and 46-60 
(9.6%, 9.8%, and 9.6% respectively). Switching was relatively less common amongst the youngest, 
and older age categories when compared with the 31-45 year reference group [OR range 0.66- 0.91}. 
Effect estimates were similar when adjusting for gender and history of psychiatric illness 
(Supplementary Table 2). There was a negative association between having an SSRI as the index AD 
and age (77.5% of those aged 76+, compared to over 90.3% in those aged <45 years).  
 
3) Clinical characteristics: Patients were more likely to switch AD if they had a lifetime, or past year 
history of self-harm [lifetime: OR 1.49, 95% CI 1.42, 1.56; past year OR 1.21, 95% CI 1.07, 1.37], or a 
history of psychiatric illness [OR 2.06, 95% CI 1.99, 2.13], depression [OR 1.92, 95% CI 1.86, 1.98] or 
anxiety [OR 1.54, 95% CI 1.50, 1.59]. Effect estimates were similar when adjusting for age and 
gender (Supplementary Table 2).There was little difference in first line AD according to lifetime 
history of anxiety or self-harm however those who had self-harmed in the past year were less likely 
than those without recent self-harm to initiate AD treatment with a TCA ( 2.6% vs 6.3%). Those with 
psychiatric illness or depression were more likely than those without to initiate treatment with an 
SSRI, and less likely to be prescribed a TCA or other AD.  
Sensitivity analysis 
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We conducted additional sensitivity analysis including prescriptions of low dose 
Amitriptyline or Nortriptyline. When including these medications, there was a considerable increase 
in the proportion of patients prescribed a TCA as the index AD (rising from 6.3% of index 
prescriptions to 31.1%). Amitriptyline or Nortriptyline together accounted for 27.8% of all index AD 
prescriptions and 89.1% of TCAs. SSRI prescriptions accounted for 64.2% of index ADs and other ADs 
accounted for 4.7%.  
The total proportion of patients who switched AD decreased slightly from 9.3% to 7.8%. This 
was largely driven by a reduction in switching amongst those prescribed a TCA (from 9.8% to 3.9%), 
as results for SSRIs and other ADs were similar to the main analysis (9.6% and 9.7%). The proportion 
of patients who switched to a TCA as a second line treatment increased from 10.7% to 16.9%. 
Amitriptyline or Nortriptyline together accounted for 7.5% of second line ADs.  
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Discussion 
Summary of main results 
We found that 9.3% of people prescribed an AD switched to a different AD product during 
their index treatment episode, indicating that initial AD treatment was likely unsatisfactory. Levels of 
switching were similar amongst those prescribed an SSRI, a TCA or other AD. In line with NICE 
guidelines (National Institute for Health and Clinical Excellence, 2009), we found that SSRIs 
accounted for the majority of first line, and second line treatments, although there was a higher 
representation of non-SSRI treatment post-switch. Characteristics associated with switching included 
male gender, younger and older age (compared with reference 31-45 year age group), lifetime 
history of self-harm, psychiatric illness, anxiety and depression.  
 
Strengths and weaknesses 
As far as we are aware, this is the first UK study to examine switching patterns in detail since 
the introduction of the 2004 NICE guidelines. Findings from studies conducted prior to this 
(Saragoussi et al., 2012, Martin et al., 1997) are based on data collected prior to 2004, and are likely 
to be less relevant to current clinical practice. The main strength of our study is the database from 
which the data were extracted. The CPRD is a large anonymised database of Primary Care Patients, 
which allowed us to examine AD switching according to individual product and class, as well as 
investigate a range of associated factors. The database provides valuable information about 
longitudinal treatment course from patients collected in a real-life setting. In order to ensure 
patients were newly started on AD they were required to have a minimum AD-free period of three 
years prior to their index date. Whist this could result in some patients being included who have 
previously had AD treatment (i.e. recurrent users rather than new starters), our exclusion period is 
much longer than many other studies, which have typically required an AD-free period of only 6 
months-1 year. We also did not restrict the period of follow-up, which allowed switching to be 
examined across the whole of the first treatment episode.  
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Findings must also be interpreted in light of several limitations. Firstly, our analysis is based 
on prescriptions issued in Primary Care, and we do not have information about those issued in other 
settings (e.g. hospital outpatients). However, the vast majority of depressed patients are treated in 
Primary Care (Tylee and Jones, 2005, Barkil-Oteo, 2013).. We also do not have information about the 
dispensing of medications or patient compliance. Secondly, we do not have data on drug efficacy, or 
tolerance, and so it was not possible to establish the reason for the AD switch, or whether this 
differed according to AD product. This is an important area for future research. Thirdly, whilst the 
CPRD is representative of UK general practices in terms of age, sex and ethnicity, it may not be not 
be representative with regards to practice size or geographical distribution (Herrett et al., 2015). 
There may also be variability across patients/practices regarding completeness of data and in the 
coding of diagnosis. Moreover, if a GP has entered diagnostic information as free text, rather than 
using a read code, then this information would likely be missed. It is also not possible within CPRD to 
identify the indication for a given medication prescription. Fourthly, data is only available to 2011, 
however, the latest guidelines were released in 2009, and so results are likely to be applicable to 
recent clinical practice. Finally, the focus of this paper was on AD switching and we did not examine 
other potential treatment patterns such as combination or augmentation treatments, or switching 
to psychotherapy.  
 
Comparison with previous literature 
The rate of switching reported in previous studies has varied considerably from 8% to 40% 
(Milea et al., 2010, Wu et al., 2013, Saragoussi et al., 2012, Andersson Sundell et al., 2013, Ball et al., 
2014, Marcus et al., 2009, Schultz and Joish, 2009). Methodological differences in study population 
and design make direct comparisons with previous research difficult. Results may be influenced by 
many factors including i) the definition of a treatment switch, ii) the length of follow-up, iii) the 
length of pre-index AD free period, iv) the time period studied, v) inclusion criteria e.g. depression 
diagnosis, vi) differences in healthcare across countries, vii) sample source/database, and  viii) the 
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number/type of ADs included in the analysis (see Supplementary Table 3 for a comparison of 
studies).   
In this study, the proportion of patients who switched AD was approximately equal across 
the AD classes. This is inconsistent with previous research suggesting that SSRIs are better tolerated 
(Barbui et al., 2000, Cipriani et al., 2009, Qin et al., 2014, Von Wolff et al., 2013) (and therefore 
would be thought to be less likely to be switched) than other ADs. However, the proportion of ‘early 
switchers’ was somewhat lower for those prescribed an SSRI compared with those prescribed a TCA 
or other AD, which could indicate that switches from SSRIs were more likely to be due to lack of 
efficacy, than to unwanted side effects. Our findings are also inconsistent with some previous 
studies that have found higher rates of switching amongst those prescribed a TCA (Milea et al., 2010, 
Saragoussi et al., 2012, Marcus et al., 2009, Wu et al., 2013, Sheehan et al., 2008), with one study 
reporting particularly high switching rates for Amitriptyline (Saragoussi et al., 2012). We excluded 
Amitriptyline and Nortriptyline from the main analysis, as they are commonly prescribed for 
indications other than depression (Ilyas and Moncrieff, 2012, Noordam et al., 2015, Marcus et al., 
2009). Sensitivity analysis found that rates of switching actually decreased when including these 
medications. We also found high rates of switching for Lofepramine (18.7%), suggesting that this TCA 
may be less effective/less well tolerated compared to other AD medications.   
Few studies have examined the longitudinal course of treatment including detailed 
descriptive information on both first and second-line ADs. Our findings are consistent with previous 
research showing that SSRIs are the preferred index AD, and that a switch to an SSRI is the most 
common pattern (Milea et al., 2010, Saragoussi et al., 2012, Andersson Sundell et al., 2013, Marcus 
et al., 2009). Prescriptions of an SSRI as a second-line treatment were comparatively lower, 
particularly when switching from another SSRI (Milea et al., 2010, Saragoussi et al., 2012). This could 
suggest that some GPs have a preference for switching to an AD with a different mechanism of 
action. Findings from the STAR*D study (Rush et al., 2006, Huynh and McIntyre, 2008) fail to support 
this view, and suggest that remission rates and adverse effects are similar for those who switch 
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between and within classes. However overall the evidence is limited and other trials have found that 
a switch to Venlafaxine after an SSRI failure appears to offer some benefit over a second SSRI 
(Connolly and Thase, 2011, Ruhé et al., 2006). Only 5.6% of patients in this sample who switched AD 
switched to Venlafaxine.   
Most switches occurred within eight weeks (60%) of the index date, with a median time to 
switch of 44 days. This is consistent with current guidelines which recommend switching within 4-8 
weeks, depending on initial response. It is also comparable to a recent US study which reported a 
median switch time of 42 days (Milea et al., 2010). We found that switching was less likely amongst 
females and amongst the younger (<18) and older (>65) age groups. The association with gender 
(Saragoussi et al., 2012, Marcus et al., 2009) and older age has also been reported in other studies 
(Milea et al., 2010, Saragoussi et al., 2012, Mullins et al., 2005), although not all findings for age have 
been consistent (Marcus et al., 2009). One hypothesis is that increasing age is associated with 
increasing compliance with treatment (Rolnick et al., 2013, Akincigil et al., 2007), or that older 
people may be prescribed lower doses, which may limit side effects. Younger people may be less 
likely to switch as alternative ADs are limited in this age group (the only AD recommended by the 
NICE guidelines is fluoxetine (National Institute for Health and Care Excellence, 2015)). The finding 
that switching was more common in males requires further exploration but could potentially reflect 
differences in the profile of adverse effects. 
Switching was also associated with lifetime history of self-harm, psychiatric illness, 
depression and anxiety. These findings are in line with previous research suggesting that switching is 
more common amongst patients who present with a more severe clinical profile (Milea et al., 2010, 
Saragoussi et al., 2012, Marcus et al., 2009). It is possible that patients presenting with more severe 
depression, or comorbidities have a reduced likelihood of response to initial monotherapy. Those 
with recent (but not lifetime) self-harm were less likely to initiate treatment with a TCA. This is in 
line with guidance which highlight the need to consider toxicity in those at risk of suicide as TCAs are 
more toxic in overdose. It is also notable that Dosulepin was prescribed both as a first-line and a 
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second-line treatment (albeit to a small proportion of patients), as this mediation is contraindicated 
due to its toxicity in overdose and increased cardiac risk (National Institute for Health and Clinical 
Excellence, 2009) .  
 
Future directions and clinical implications 
Non-response to AD treatment is a substantial problem in Primary Care (Thomas et al., 
2013c); many patients with depression do not achieve remission with monotherapy, and require 
additional interventions. Further research is needed comparing different pharmacological and 
psychological second-line treatment strategies including switching, combination and augmentation 
treatment, in order to inform guidelines and improve patient outcomes.  
When switching AD, UK treatment guidelines suggest switching to another SSRI, or to a 
better-tolerated newer-generation AD such as Mirtazapine (National Institute for Health and Clinical 
Excellence, 2009). However, the evidence to support best practice in this area is currently very 
limited; few high-quality RCTs have investigated the efficacy of switching antidepressants (Connolly 
and Thase, 2011, Anderson et al., 2008) and results have not been consistent. Moreover, findings 
from clinical trials may not generalise to routine clinical practice and so additional studies are 
needed which build on the work from this study, and examine AD switching in real-life settings. 
More research is also needed exploring the reasons why patients switch medications, and the 
impact this may have on their treatment and outcome.  
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Table 1: Antidepressant switch according to product  
AD product a 
First-line AD (% 
of total sample) 
Number who 
switched (% of 
index drug) 
median time to 
switch, days 
(IQ range) 
Number switched 
within 
recommended time 
frame (4-8 weeks) 
Early 
switchers (<4 
weeks) 
Late switchers 
(>8 weeks) 
Second line 
AD (% of 
those who 
switched) 
TCAs        
Amitriptyline hydrochloride 2509 (1.0%) 171 (6.8%) 63 (23,183) 27 (15.8%) 52 (30.4%) 92 (53.8%) 130 (0.5%) 
Dosulepin hydrochloride 6,821 (2.6%) 624 (9.1%) 38 (21, 75) 175 (28.0%) 247 (39.6%) 202 (32.4%) 876 (3.6%) 
Imipramine hydrochloride 1185 (0.5%) 63 (5.3%) 49 (29, 84) 24 (38.1%) 15 (23.8%) 24 (23.8%) 78 (0.3%) 
Lofepramine 1,494 (0.6%) 280 (18.7%) 35 (21, 67) 79 (28.2%) 119 (42.5%) 82 (29.3%) 739 (3.0%) 
Trazodone hydrochloride 2,795 (1.1%) 296 (10.8%) 36 (18, 74) 69 (23.3%) 126 (42.6%) 101 (34.1%) 597 (2.4%) 
Other TCAs 1,711 (0.7%) 171 (10.0%) 34 (14, 96) 34 (19.9%) 78 (45.6%) 59 (34.5%) 207 (0.8%) 
Total TCAs 16,453 (6.3%) 1,605 (9.8%) 38 (21, 83) 408 (25.4%) 637 (39.7%) 560 (34.9%) 2627 (10.7%) 
SSRIs         
Citalopram hydrobromide/ 
Citalopram hydrochloride 127,458 (48.5%) 10,401 (8.2%) 46 (22, 105) 
 
2,437 (23.4%) 
 
3,583 (34.5%) 
 
4,381 (42.1%) 6,310 (25.8%) 
Escitalopram oxalate 12,523 (4.8%) 1,443 (11.5%) 63 (28, 210) 288 (20.0%) 392 (27.2%) 763 (52.3%) 1,433 (5.9%) 
Fluoxetine hydrochloride 68,442 (26.0%) 7,353 (10.7%) 43 (23, 90) 1,963 (26.7%) 2,537 (34.5%) 2,853 (38.8%) 4,271 (17.5%) 
Paroxetine hydrochloride 3,681 (1.4%) 416 (11.3%) 36 (20, 84) 108 (26.0%) 162 (38.9%) 146 (35.1%) 559 (2.3%)  
Sertraline hydrochloride 16,295 (6.2%) 1,591 (9.8%) 39 (19, 84) 355 (22.3%) 665 (41.8%) 571 (35.9%) 3,183 (13.0%) 
Other SSRIs (fluvoxamine maleate) 53 (<0.1%) 4 (7.5%) 164 (40, 306) 0 (0%) 1 (25.0%) 3 (75.0%) 19 (0.1%) 
Total SSRIs 228,452 (86.9%) 21,208 (9.3%) 45 (22, 101) 5,151 (24.3%) 7,340 (34.6%) 8,717 (41.1%) 15,775 (64.5%) 
Other        
Duloxetine hydrochloride 3,947 (1.5%) 132 (3.3%) 42 (24, 91) 36 (27.3%) 46 (34.8%) 50 (37.9%) 601 (2.5%) 
Flupentixol dihydrochloride 1,498 (0.6%) 188 (12.6%) 35 (21, 63) 60 (31.9%) 76 (40.4%) 52 (27.7%) 92 (0.4%) 
Mirtazapine 10,581 (4.0%) 1,152 (10.9%) 35 (17, 76) 258 (22.4%) 516 (44.8%) 378 (32.8%) 3,958 (16.2%) 
Venlafaxine hydrochloride 1,854 (0.7%) 176 (9.5%) 36 (17, 79) 54 (30.7%) 67 (38.1%) 55 (31.2%) 1,367 (5.6%) 
Other  59 (<0.1%) 10 (16.9%) 23 (10, 40) 2 (20.0%) 6 (60.0%) 2 (20.0%) 51 (0.2%) 
Total other AD 17,939 (6.8%) 1,658 (9.2%) 35 (18, 74) 410 (24.7%) 711 (42.9%) 537 (32.4%) 6,069 (24.8%) 
All AD products (n=262,844)  24,471 (9.3%) 44 (22, 98) 5,969 (24.4%) 8,688 (35.5%) 9,814 (40.1%)  
a Within each AD class,  medications accounting for >0.5% of first line ADs were grouped together to form an ‘other’ category 
Firstline: the index antidepressant; secondline: the second prescribed antidepressant  
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Table 2: Pattern of AD switching according to drug class (percentage of those who have switched, 
n= 24,471)  
 
 Second line treatment 
TCA SSRI Other 
First line treatment     
TCA 163 (0.7%) 1,210 (4.9%) 232 (0.9%) 
SSRI 2,282 (9.3%) 13,235 (54.1%) 5,691 (23.3%) 
Other  182 (0.7%) 1,330 (5.4%) 146 (0.6%) 
All AD  2,627 (10.7%) 15,775 (64.5%) 6,669 (24.8%) 
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Table 3: Characteristics associated with AD switching  
 First line SSRI First line TCA First line other AD Switched AD Did not switch AD OR (95%CI) P value  
Gender        
Females  142,964 (84.8%) 13,662 (8.1%) 11,938 (7.1%) 14,699 (8.7%) 153,865 (91.3%) Reference   
Males 85,488 (90.7%) 2,791 (2.9%) 6,001 (6.4%) 9,772 (10.4%) 84,508 (89.6%) 1.21 [1.18, 1.24] <0.001 
        
Age       Omnibus P for age 
<0.001 
<18 4,219 (92.6%) 220 (4.8%) 117 (2.6%) 306 (6.7%) 4,250 (93.3%) 0.66 [0.59, 0.74] <0.001 
18-30 48,474 (92.9%) 1,615 (3.1%) 2,098 (4.0%) 5,000 (9.6%) 47,187 (90.4%) 0.97 [0.94, 1.01] 0.153 
31-45 66,133 (90.3%) 3,521 (4.8%) 3,548 (4.9%) 7,191 (9.8%) 66,011 (90.2%) 1.00 - 
46-60 56,310 (86.0%) 4,496 (6.9%) 4,642 (7.1%) 6,286 (9.6%) 59,162 (90.4%) 0.98 [0.94, 1.01] 0.170 
61-75 30,710 (80.2%) 3,754 (9.8%) 3,837 (10.0%) 3,454 (9.0%) 34,847 (91.0%) 0.91 [0.87, 0.95] <0.001 
76+ 22,606 (77.5%) 2,847 (9.8%) 3,697 (12.7%) 2,234 (7.7%) 26,916 (92.3%)  0.76 [0.73, 0.80] <0.001 
History of self-harm        
No 214,820 (86.9%) 15,540 (6.3%) 16,788 (6.8%) 22,439 (9.1%) 224,709 (90.9%) Reference   
Yes 13,632 (86.9%) 913 (5.8%) 1,151 (7.3%) 2,032 (13.0%) 13,664 (87.0%) 1.49 [1.42, 1.56] <0.001 
        
Past year self-harm         
No 226,167 (86.9%) 16,387 (6.3%) 17,708 (6.8%) 24,186 (9.3%) 236,076 (90.7%) Reference   
Yes 2,285 (88.5%) 66 (2.6%) 231 (8.9%) 285 (11.0%) 2,297 (89.0%) 1.21 [1.07, 1.37] 0.002 
History of psychiatric 
illness   
       
No 61,659 (81.2%) 6,821 (9.0%) 7,418 (9.8%) 4,230 (5.6%) 71,668 (94.4%) Reference  
Yes 166,793 (89.2%) 9,632 (5.2%) 10,521 (5.6%) 20,241 (10.8%) 166,705 (89.1%) 2.06 [1.99, 2.13] <0.001 
History of depression        
No 76,645 (82.1%) 8,372 (9.0%) 8,329 (8.9%) 5,699 (6.1%) 87,647 (93.9%) Reference  
Yes 151,807 (89.5%) 8,081 (4.8%) 9,610 (5.7%) 18,772 (11.1%) 150,726 (88.9%) 1.92 [1.86, 1.98] <0.001 
History of anxiety        
No 146,208 (86.4%) 10,894 (6.4%) 12,192 (7.2%) 13,457 (7.9%) 155,837 (92.1%) Reference  
Yes 182,244 (87.9%) 5,559 (5.9%) 5,747 (6.1%) 11,014 (11.8%) 82,536 (88.2%) 1.54 [1.50, 1.59] <0.001 
 
